MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Open

36.43 -2.04

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.81

Max

37.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -102M
Angestellte	258
EBITDA	-30M -109M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+42.22% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	141M 5.7B
Vorheriger Eröffnungskurs	38.47
Vorheriger Schlusskurs	36.43

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. Apr. 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. Apr. 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. Apr. 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. Apr. 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. Apr. 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. Apr. 2026, 22:31 UTC

Wichtige Nachrichtenereignisse

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. Apr. 2026, 22:31 UTC

Wichtige Nachrichtenereignisse

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. Apr. 2026, 20:57 UTC

Wichtige Nachrichtenereignisse

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Apr. 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. Apr. 2026, 20:25 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Apr. 2026, 19:30 UTC

Wichtige Nachrichtenereignisse

How Digital Currencies Have Helped Iran -- WSJ

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

42.22% Vorteil

12-Monats-Prognose

Durchschnitt 52.55 USD 42.22%

Hoch 64 USD

Tief 35 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.